Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03874299
Other study ID # 16-004433
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 17, 2016
Est. completion date June 20, 2019

Study information

Verified date September 2022
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The researchers are trying to develop a way to measure the risk of rejection through the validation of a blood test.


Recruitment information / eligibility

Status Completed
Enrollment 302
Est. completion date June 20, 2019
Est. primary completion date June 20, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult (>/=18 years) renal transplant recipient. - Patients who have given informed consent and are willing to comply with the protocol, including the use of their peripheral blood specimens and data for subsequent research. Exclusion Criteria: -Adult (<18 years) renal transplant recipient.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Mayo Clinic Jacksonville Florida
United States Mayo Clinic Rochester Minnesota
United States Mayo Clinic Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To validate the use of a RNA-seq based peripheral blood assay in renal transplant recipients. The study will validate the ability of a peripheral blood assay to assess the risk of biopsy proven rejection. 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT04491552 - TruGraf® Long-term Clinical Outcomes Study
Withdrawn NCT04560582 - Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Completed NCT05747274 - SRDK0921_ Analytical Performance Study
Not yet recruiting NCT05482100 - CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients
Recruiting NCT06243289 - Improving KIdney Transplantation With Cellular Therapy Study
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed NCT04367610 - Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Enrolling by invitation NCT06126380 - Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients Phase 2
Terminated NCT05747053 - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Active, not recruiting NCT03714113 - Donor-specific Anti-HLA Antibodies Monitoring in Kidney Transplant Recipients N/A
Recruiting NCT04091984 - The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
Recruiting NCT05335538 - TruGraf and TRAC In Pediatrics Study
Completed NCT03663335 - Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients Phase 2
Completed NCT03652402 - Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN
Recruiting NCT04773392 - Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR Phase 4
Terminated NCT02974686 - Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation Phase 4
Completed NCT03873623 - The TOGETHER Project - Kidney
Terminated NCT04156204 - Immunosuppressant Medication Dosed Daily After Kidney Transplant Early Phase 1
Completed NCT04601155 - Transition of Renal Patients Using AlloSure Into Community Kidney Care
Completed NCT03965559 - The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant

External Links